Intraperitoneal immunotherapy using p53-armed oncolytic Ad (OBP-702) increased the recruitment of tumor-infiltrating lymphocytes (TILs) via the functional remodeling of intraperitoneal macrophages from TAMs toward a pro-inflammatory phenotype and enhanced the efficacy of ICIs. Here, TP53 is linked to neoplasm.